JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online January 21, 2009, 10.2967/jnumed.108.056655
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Activity
Right arrow All Versions of this Article:
jnumed.108.056655v1
50/2/239    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, B.
Right arrow Articles by Larson, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, B.
Right arrow Articles by Larson, S. M.
Journal of Nuclear Medicine Vol. 50 No. 2 239-249
© 2009 by Society of Nuclear Medicine
doi: 10.2967/jnumed.108.056655

Continuing Education

Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers*

Binsheng Zhao1,2, Lawrence H. Schwartz2 and Steve M. Larson2

1 Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York; and 2 Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints contact: Binsheng Zhao, Departments of Medical Physics and Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. E-mail: zhaob{at}mskcc.org

This article addresses the current status of quantitative imaging as a surrogate biomarker for the assessment of tumor response to therapy with non–small cell lung cancer as an example. In addition, the article discusses the limitations of conventional response criteria in the new era of molecular-targeted agents for cancer treatment; the increasing need for more accurate and early response-assessment methods, particularly for volumetric CT; new tumor-specific radiotracers and molecular imaging technologies; and the future applications of molecular imaging with PET for studying various features of cancer metabolism, endocrine status, hypoxia, and oncofetal and differentiation antigens.

Key Words: response assessment • surrogate biomarker • functional/molecular imaging • volumetric CT • lung cancer

* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH FEBRUARY 2010.

Dr. Larson reports having a financial interest in Philips ADAC, Novartis Pharmaceutical Corp., Wilex AG, Bayer HealthCare, Cellector, GE Amersham, CTI Siemens, and Genentech. Dr. Schwartz reports having an affiliation with GE Medical Systems, Bio-Imaging, Novartis, Merck, and AstraZeneca. No other potential conflict of interest relevant to this article was reported.

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.